$8.78
3.41% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US71722W1071
Symbol
PHAT
Sector
Industry

Phathom Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
6 days ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Sa...
Neutral
GlobeNewsWire
12 days ago
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
Neutral
GlobeNewsWire
19 days ago
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
Neutral
GlobeNewsWire
20 days ago
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American Colle...
Neutral
GlobeNewsWire
3 months ago
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
Neutral
GlobeNewsWire
3 months ago
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares o...
Neutral
Seeking Alpha
3 months ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - ...
Neutral
GlobeNewsWire
3 months ago
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter of 2024, and provided recent business updates.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today